factor-1

Complement factor D-IN-1 is a potent and selective small-molecule reversible Factor D inhibitor, with IC50 values of 0.006 μM in the FD Thioesterolytic Fluorescent Assay and 0.05 μM in the MAC Deposition Assay.

NFAT Transcription Factor Regulator-1 is a synthesis inhibitor of IL-2 with an IC50 of 182 nM.

eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 1) is expressed

Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-derived aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. aFGF (1-11) corresponds to amino acid residues 1-11 of the full length peptide.

Brain-derived basic fibroblast growth factor (1-24) (brain-derived bFGF) is a peptide fragment of brain-derived bFGF. bFGF is a peptide produced in bovine brain that is protective in a rat model of pressure-induced retinal ischemia. bFGF (1-24) corresponds to amino acid residues 1-24 of the full length peptide.

Factor B-IN-1 is a Factor B inhibitor (IC50 = 43 nM) and is an analog of compound 13. It is used to inhibit complement pathway factor B and has improved pharmacokinetic properties (oral availability in rats and dogs).

Atrial natriuretic factor (1-28) from both human and porcine sources is a potent suppressor of pro-opiomelanocortin (POMC) mRNA, exerting only a modest inhibitory effect on βEP-LI release.

Elongation factor P-IN-1, a potent elongation factor P (EFP) inhibitor and β-lysine derivative compound, affects E. coli proliferation rate[1].

Factor VII-IN-1 (example 43) exhibits anticoagulant activities as a potent factor VII (FVII) inhibitor with an IC50 value of 1.1 μM [1].

Factor XI-IN-1 is an inhibitor of factor XI activation (EC50: 25.14 nM).

Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24), a synthetic peptide with anti-bacterial and anti-HBV properties, is utilized in infectious and immune disease research [1].

Mating Factor α (1-6), a compound secreted by α-mating type cells of Saccharomyces cerevisiae, functions as an inhibitor of DNA synthesis initiation in these cells [1].

Epigenetic factor-IN-1 (40569Z) is an inhibitor that exhibits potent binding affinity for SIRT7 and is utilized in the study of liver cancer [1].

Transcription factor-IN-1 (Compound 4e) acts as an inhibitor of transcription factors. It exhibits anticonvulsant activity by antagonizing pentylenetetrazole (PTZ) with an ED50 of 34.5 mg kg. Additionally, Transcription factor-IN-1 demonstrates antidepressant activity in a rat model.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits antihypertensive activity by promoting sodium and urine excretion. It inhibits the release of adrenocorticotropic hormone (ACTH) and β-endorphin by suppressing pro-opiomelanocortin (POMC) expression. Additionally, it elevates cGMP levels in RMIC cells, with an IC50 of 1.2 nM.

Brain Derived Acidic Fibroblast Growth Factor (1-11) is a polypeptide molecule with the sequence PALPEDGGSGAFPPGHFKDPKRLY.

Hypercalcemia Malignancy Factor (1-34), human is a polypeptide molecule with the sequence AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA.

Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6 22 90 15 20 20 57 58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Disitertide acetate (P144 acetate) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide acetate is also a PI3K inhibitor and an apoptosis inducer.

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM.

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.